June 2-6, 2017 Chicago, IL Booth #2124 Precision will be exhibiting again at ASCO this summer in Chicago. Look for us on the exhibitor floor in Booth #2124 meet with our oncology experts.
May 20-24, 2017 Boston, MA Booth#909 Precision will have a very strong presence again at ISPOR-- this year in Boston, MA. Come see us on the convention floor at Booth #909, and look for our expertise on display in numerous Precision-led short courses, forums, posters, issues panels, workshops and plenary sessions.
Date: March 27, 2017 – March 30, 2017 AMCP is coming to Denver March 27th -30th, and Precision is looking forward to the chance to show off our capabilities and experts with a booth presence, three presentations, four posters and more! […]
Precision for Value president Dan Renick is interviewed for Pharmaceutical Commerce, providing his in-depth perspective on today's payer and provider markets.
In a new article for Clinical Leader, PHE’s Ross Maclean and Jeroen Jansen explain how evidence synthesis can reduce the guesswork of clinical trial design.
A large manufacturer client was preparing to launch a biosimilar into a highly competitive and complex market. In this case study, the brand team sought to learn how payers would view the product in relation to key competitors, understand decision drivers and thresholds, and identify potential competitive reactions resulting from any actions taken.
Learn how one pharmaceutical manufacturer overcame inconsistencies in tracking payer coverage and performance across the organization. With the application of a Payer Plan Hierarchy, the client was able to better understand the payer landscape and had a more direct and consistent line of sight on supporting product performance in managed markets contexts.
How is value defined in cancer care? What do patients value most?
Precision for Value’s Jeremy Schafer comments on pricing and reimbursement of dupilumab, Sanofi/Regeneron’s first atopic dermatitis biologic, in BioPharm Insight.
Precision for Value’s Hepatitis C Survey Discussed in Managed Healthcare Executive: Here’s What’s Missing
Precision for Value’s Jeremy Schafer highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.